All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Six weeks after divesting its portfolio of marketed cancer drugs, Glaxosmithkline (GSK) plc is stepping up investment in oncology R&D, in a $350 million deal with T-cell immunotherapy specialist, Adaptimmune Ltd., for its lead program NY-ESO-1.